Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Everest Medicines Ltd. ( (HK:1952) ) has issued an announcement.
Everest Medicines Limited has announced a delay in sending a shareholder circular relating to its continuing connected transactions under a Commercialization Service Agreement. The circular, which will include details of the agreement, recommendations from the Independent Board Committee, and advice from an Independent Financial Adviser ahead of an extraordinary general meeting, was originally expected by 16 January 2026 but will now be published on or before 4 February 2026 due to additional time needed to prepare and finalize the information, potentially shifting the timeline for shareholder review and approval of the transaction.
The most recent analyst rating on (HK:1952) stock is a Hold with a HK$38.00 price target. To see the full list of analyst forecasts on Everest Medicines Ltd. stock, see the HK:1952 Stock Forecast page.
More about Everest Medicines Ltd.
Everest Medicines Limited is a biopharmaceutical company listed in Hong Kong that focuses on developing and commercializing innovative medicines, with a particular emphasis on licensed products and partnerships in Asian markets.
Average Trading Volume: 3,711,272
Technical Sentiment Signal: Sell
Current Market Cap: HK$14.07B
See more insights into 1952 stock on TipRanks’ Stock Analysis page.